Clinical trials: Breast Cancer Risk
Evaluation Studies, Implementation Research
Implementation of the Begin Exploring Fertility Options, Risks and Expectations (BEFORE) Decision Aid
The Begin Exploring Fertility Options, Risks and Expectations (BEFORE) decision aid was created to support fertility discussions and decision-making for young breast cancer patients in Canada.
- Conditions
- Evaluation Studies, Implementation Research, Decision Aid, Young Adult Cancer
- Trial name
- BEFORE (NCT03629509)
- Testing
- Educational Webinar and Resources
- Where
- Canada
- Volunteers
- 116 people
- Sponsor
- Unity Health Toronto
Breast Cancer
Sunitinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Who Have Tumor Cells in the Bone Marrow
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00824538
- Testing
- sunitinib malate, flow cytometry, immunohistochemistry staining method
- Volunteers
- 13 people
- Sponsor
- University of California, San Francisco
Breast Cancer
S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00070564
- Testing
- pegfilgrastim, AC regimen, cyclophosphamide
- Where
- 542 sites in United States, Canada and 1 more
- Volunteers
- 3,294 people
- Sponsor
- SWOG Cancer Research Network
Cardiotoxicity, Toxicity Due to Chemotherapy
Pilot Study of an NTproBNP Guided Strategy of Cardioprotection
Investigators will evaluate the safety and feasibility of a biomarker-guided cardioprotection strategy using NTproBNP, as compared to usual care, in breast cancer and lymphoma patients treated with anthracyclines.
- Conditions
- Cardiotoxicity, Toxicity Due to Chemotherapy, Breast Cancer, Lymphoma
- Trial name
- NTproBNP-Guide (NCT04737265)
- Testing
- Biomarker Guided Intervention
- Where
- 3 sites in United States
- Volunteers
- 108 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Carcinoma
Lifestyle Intervention for the Reduction of Breast Cancer Risk in Normal Weight Women
This trial studies how well a lifestyle intervention works in reducing breast cancer risk through changing body composition and decreasing inflammation in normal weight women.
- Trial name
- NCT04267796
- Testing
- Aerobic Exercise, Dietary Intervention, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Zoledronate in Treating Bone Marrow Micrometastases in Women With Stage I, Stage II, or Stage III Breast Cancer
RATIONALE: Zoledronate may delay or prevent bone marrow metastases in patients with breast cancer. PURPOSE: This phase II trial is studying how well zoledronate works in treating bone marrow micrometastases in women with stage I…
- Trial name
- NCT00295867
- Testing
- Zoledronic Acid
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of California, San Francisco
Breast Neoplasm, Primary Prevention
Project Breast47: Effect of an Educational Intervention
Breast cancer is the most frequently diagnosed malignant tumor in women. In 2018, in Spain, the estimated incidence was 101/100,000 women.
- Conditions
- Breast Neoplasm, Primary Prevention, Risk Factors, Telemedicine
- Trial name
- Breast47 (NCT05267171)
- Testing
- Web access
- Where
- Spain
- Volunteers
- 451 people, healthy volunteers welcome
- Sponsor
- University of Oviedo
Breast Cancer
Pilot Study of the Effect of Duavee® on Benign Breast Tissue Proliferation
The purpose of this study is to learn whether daily use of Duavee® is accepted and tolerated by peri- and post-menopausal women at moderate risk for development of breast cancer.
- Trial name
- NCT02729701
- Testing
- Duavee
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- University of Kansas Medical Center
Breast Cancer
Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score
The purpose of this study is to see whether adding everolimus to hormone treatment before breast surgery will increase the chances of shrinking the breast cancer in those patients with hormone-responsive breast cancer and a lower…
- Trial name
- NCT02236572
- Testing
- Everolimus
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Yale University
HER2/Neu Positive, Progesterone Receptor Positive
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
This randomized phase III clinical trial studies chemotherapy with or without trastuzumab after surgery to see how well they work in treating women with invasive breast cancer.
- Conditions
- HER2/Neu Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IA Breast Cancer AJCC v7
- Trial name
- NCT01275677
- Testing
- Cyclophosphamide, Docetaxel, Doxorubicin
- Where
- 1,283 sites in United States, Canada and 2 more
- Volunteers
- 3,270 people
- Sponsor
- National Cancer Institute (NCI)
Cardiotoxicity, Risk Factor, Cardiovascular
Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab
Investigators will evaluate the safety, tolerability, and feasibility of a risk-guided cardioprotective treatment strategy with carvedilol, as compared to usual care, in breast cancer patients undergoing treatment with…
- Conditions
- Cardiotoxicity, Risk Factor, Cardiovascular, Toxicity Due to Chemotherapy, Breast Cancer
- Trial name
- CCTGuide Pilot (NCT04023110)
- Testing
- Carvedilol
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Cancer
HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer
The purpose of this study is to determine the safety and immunogenicity of HER-2 pulsed DC1 vaccine in high risk HER-2 high and intermediate expression breast cancers.
- Trial name
- Adjuvant (NCT02063724)
- Testing
- HER-2 pulsed Dendritic Cell Vaccine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Breast Cancer
Vaccine Therapy in Treating Patients at High Risk for Breast Cancer Recurrence
RATIONALE: Vaccines may make the body build an immune response and decrease the recurrence of breast cancer. PURPOSE: Pilot trial to study the effectiveness of vaccine therapy in treating patients who are at high risk for breast…
- Trial name
- NCT00030823
- Testing
- Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine, QS21
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
Case-Control-Study on the Breast Cancer Risk of Mirena® Compared With Copper IUDs
The objective of this study is to determine the breast cancer risk of Mirena® users compared to copper intrauterine device (IUD) users in a community-based case-control study.
- Trial name
- NCT00461253
- Testing
- Levonorgestrel-releasing IUD, Copper IUD
- Where
- Germany
- Volunteers
- 25,565 people, healthy volunteers welcome
- Sponsor
- Center for Epidemiology and Health Research, Germany
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer
This phase II trial studies how well docetaxel or paclitaxel work in reducing chemotherapy-induced peripheral neuropathy in African American patients with stages I-III breast cancer.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT04001829
- Testing
- Docetaxel, Paclitaxel, Quality-of-Life Assessment
- Where
- 482 sites in United States
- Volunteers
- 249 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Breast Cancer
Soy Protein and Breast Cancer Risk Reduction
Soy consumption has been associated with reduced risk for developing breast cancer. Ovarian hormones and breast density are considered breast cancer risk markers.
- Trial name
- NCT00204477
- Testing
- soy milk, cow's milk
- Where
- United States
- Volunteers
- 321 people, healthy volunteers welcome
- Sponsor
- The University of Texas Medical Branch, Galveston
Stage IV Breast Cancer
Vaccination of High Risk Breast Cancer Patients
Objective - Determine the safety and tolerability of a peptide mimotope-based vaccine upon immunization of breast cancer subjects.
- Trial name
- NCT01390064
- Testing
- Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Arkansas
Breast Cancer
FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients
This is a prospective, open-label, randomized, phase III trial. Patients will be stratified after breast surgery, as per investigational site; menopausal status; node negative diagnosis, as per sentinel-node technique versus…
- Trial name
- NCT00129389
- Testing
- Fluorouracil, Doxorubicin, Cyclophosphamide
- Where
- 68 sites in Spain
- Volunteers
- 1,925 people
- Sponsor
- Spanish Breast Cancer Research Group
Breast Cancer
Study of Vitamin D for Premenopausal Women at High Risk for Breast Cancer
This proposal is for a pilot study of 20 premenopausal women at high risk for breast cancer development who will receive high dose vitamin D3, cholecalciferol 20,000 IU (2 capsules) weekly, or 30,000 IU (3 capsules) weekly, for 1…
- Trial name
- NCT00976339
- Testing
- Cholecalciferol
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Katherine D. Crew
Lymphedema, Breast Cancer
Lymphedema Prophylaxis in Breast Cancer Survivors Who Show Early Evidence of High-risk Status
To compare the effectiveness of usual treatments for lymphedema [massage and elastic compression sleeve, instituted at-risk and before the development of swelling (lymphedema)], compared to the use of a newly-marketed device, the…
- Trial name
- NCT00383500
- Testing
- Flexitouch, Class 1 compression garment
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Stanford University